Reductions in DSQ total score were first observed at Week 4 with treatment with DUPIXENT 300 mg QW (post-hoc analysis; results are descriptive).3

DUPIXENT significantly reduced DSQ total scores compared to placebo at Week 24 (coprimary endpoint).1,3

DSQ total score reductions were observed for up to 52 weeks with continued weekly DUPIXENT treatment (secondary endpoint).3

Extended active treatment period, results are descriptive at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.3

Total biweekly DSQ scores range from 0 to 84; higher scores indicate greater frequency and severity of dysphagia.1